Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$29.35 USD

29.35
3,320,301

+0.85 (2.98%)

Updated Oct 16, 2024 04:00 PM ET

After-Market: $29.38 +0.03 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Emergent BioSolutions to Buy Sanofi's Smallpox Vaccine Unit

Emergent BioSolutions Inc. (EBS) announced that it has inked an agreement to acquire the FDA-licensed smallpox vaccine's business of Sanofi (SNY) in an all-cash deal of up to $125 million.

    Why Are Shares of Exelixis (EXEL) Up 77% So Far in 2017?

    Shares of Exelixis, Inc. (KITE) have gained almost 4.68% on Aug 12. The company's shares have rallied a whopping 77% this year so far, outperforming the 7.8% increase registered by the Zacks categorized industry during this period.

      BioDelivery-Purdue Pharma Ink Marketing Deal for Pain Drug

      BioDelivery Sciences International, Inc. (BDSI) announced an exclusive partnership agreement with Purdue Pharma, a Canadian pharmaceutical company, for commercializing its pain drug Belbuca in Canada.

        Endocyte (ECYT) to Focus on Promising CAR-T Cell Platform

        We issued an updated research report Endocyte, Inc. (ECYT) on Jul 12.

          Why Exelixis (EXEL) Could Be an Impressive Growth Stock

          Exelixis (EXEL) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.

            Arena Announces Secondary Stock Offering of 150M Shares

            Arena Pharmaceuticals, Inc. (ARNA) plans to offer and sell 150 million shares of its common stock, subject to customary closing conditions.

              David Bartosiak headshot

              Five Scorching Hot Stocks Screaming Higher

              Five Zacks Rank #1 (Strong Buy) stocks at 52-week highs pushing even higher

                Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx

                Exelixis (EXEL) initiated a phase III trial, CheckMate 9ER to evaluate Opdivo in combination with Cabometyx or Opdivo and Yervoy in combination with Cabometyx versus Sutent in patients with RCC.

                  The Zacks Analyst Blog Highlights: Malibu Boats, Addus Homecare, Exelixis, Gran Tierra Energy and Delek Logisitcs Partners

                  The Zacks Analyst Blog Highlights: Malibu Boats, Addus Homecare, Exelixis, Gran Tierra Energy and Delek Logisitcs Partners

                    Brian Bolan headshot

                    Best Stocks For The Second Half of 2017

                    A look at some stocks that are expected to show some good growth in the back half of the year.

                      AVEO's Kidney Cancer Candidate Gets CHMP Recommendation

                      AVEO Pharmaceuticals, Inc. (AVEO) announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its lead candidate, Fotivda (tivozanib), for the treatment of advanced renal cell carcinoma (RCC).

                        Cara Therapeutics (CARA) Shows Strength: Stock Adds 12.2 % in Session

                        Cara Therapeutics, Inc. (CARA) was a big mover last session, as the company saw its shares rise over 12% on the day

                          Top Ranked Momentum Stocks to Buy for June 27th

                          Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 27th:

                            AVEO Reaches Enrollment Target in Pivotal Tivozanib Study

                            AVEO Pharmaceuticals, Inc. (AVEO) announced that the phase III study, TIVO-3, evaluating tivozanib in patients with refractory advanced renal cell carcinoma (RCC) has reached its enrollment target

                              Exelixis's Cabometyx Positive for First-Line Kidney Cancer

                              Exelixis, Inc. (EXEL) announced results from an analysis of the data from the phase II trial, CABOSUN evaluating Cabometyx to Sutent for kidney cancer.

                                Exelixis Initiates Cabozantinib-Tecentriq Combination Trial

                                Exelixis, Inc. (EXEL) announced that it initiated the dose-escalation stage of a phase Ib trial of cabozantinib in combination with Roche's (RHHBY) Tecentriq.

                                  Pfizer's Kidney Cancer Drug Gets Acceptance in the U.S. & EU

                                  Pfizer Inc. (PFE) announced encouraging news with the FDA and the European Medicines Agency (EMA) accepting the company's regulatory submission for label expansion of its cancer drug, Sutent (sunitinib).

                                    Why Is Exelixis (EXEL) Down 20.9% Since the Last Earnings Report?

                                    Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                      Zacks.com featured highlights: Sonus Networks, CNH Industrial, WellCare Health Plans, Exelixis and Best Buy

                                      Zacks.com featured highlights: Sonus Networks, CNH Industrial, WellCare Health Plans, Exelixis and Best Buy

                                        Exelixis (EXEL) Posts Earnings in Q1, Cabometyx in Focus

                                        Exelixis posted earnings in the first quarter of 2017 while revenues beat estimates driven by Cabometyx.

                                          Play Potential Earnings Beat with These 5 Top-Ranked Stocks

                                          Bet on these top-ranked stocks that have the potential to beat the earnings estimate.

                                            Is Intercept (ICPT) Poised for a Beat This Earnings Season?

                                            Is Intercept (ICPT) Poised for a Beat this Earnings Season?

                                              Apple (AAPL) to Report Q2 Earnings: Is a Beat in Store?

                                              Apple, Inc. (AAPL) is set to report its second-quarter fiscal 2017 results on May 2.

                                                What to Expect from Quotient Technology (QUOT) Q1 Earnings?

                                                Quotient Technology Inc. (QUOT) is set to report first-quarter 2017 results on May 2.

                                                  Insperity (NSP) Q1 Earnings: Is a Surprise in the Cards?

                                                  Insperity, Inc. (NSP) is set to report first-quarter 2017 results on May 1.